Beth Israel Deaconess Medical Center





Harvard Medical School

Assistant Professor of Medicine Member, Harvard Institute of Human Genetics

Director, Biotherapeutics Development Laben, Division of Hematology-Oncology

Beth Israel Deaconess Medical Center Harvard Institutes of Medicine

Richard P. Junghans, PhD, MD

4 Blackfan Circle, #403 • Boston, MA 02215 USA 617 432-7004 • FAX 617 432-7007 email: junghans@hms.harvard.edu

March 27, 2002

Director of the United States Patent and Trademark Office United States Patent and Trademark Office Washington, D.C. 20231

To Whom It May Concern:

As requested, attached are the Abstract, newly executed oath, a copy of the Sequence Listing with an amendment, a CRF (computer readable form) of the Sequence Listing along with a copy of the 1/28/2002 "Notice of Incomplete Nonprovisional Application" for application No. 10/006,773. The data contained in the CRF are identical to the written sequence and contain no new matter. The \$42 for 1 independent claims over 3 surcharge may be charged to my Visa Card Account shown on the attached USPTO Credit Card Payment Form.

Please call my administrative assistant, Iris Bradley, with any questions.

Thank you.

Sincerely,

W

40

Richard P. Junghans, Ph.D., M.D.

Encl.

RPJ/ib



Richard P. Junghans, Ph.D., M.D.

One Lyndeboro Place

Boston, MA 02116

Gommissioner for Patents United States Patent and Trademark Office Washington, D.C. 2023 www.usplo.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/006,773

12/10/2001

Richard P. Junghans

**CONFIRMATION NO. 2051** 

FORMALITIES LETTER

\*OC000000007373530\*

Date Mailed: 01/28/2002

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

## Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- · Abstract must be on a separate sheet.
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.



The required items noted below SHOULD be filed along with any items required above. The filing date of this nonprovisional application will be the date of the items required above.

- Total additional claim fee(s) for this application is \$42.
  - \$42 for 1 independent claims over 3.
- The balance due by applicant is \$ 42.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE